Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer

被引:184
作者
Higashi, K
Ueda, Y
Sakurai, A
Wang, XM
Xu, LF
Murakami, M
Seki, H
Oguchi, M
Taki, S
Nambu, Y
Tonami, H
Katsuda, S
Yamamoto, I
机构
[1] Kanazawa Med Univ, Dept Radiol, Uchinada, Ishikawa 9200293, Japan
[2] Kanazawa Med Univ, Dept Pathol, Uchinada, Ishikawa 92002, Japan
[3] Kanazawa Med Univ, Dept Internal Med, Div Resp Dis, Uchinada, Ishikawa 92002, Japan
[4] Kanazawa Med Univ, Med Res Inst, Uchinada, Ishikawa 92002, Japan
[5] Kanazawa Cardiovasc Hosp, Dept Radiol, Kanazawa, Ishikawa, Japan
关键词
fluorine-18; fluorodeoxyglucose; positron emission tomography; lung cancer; glucose transporter;
D O I
10.1007/s002590000367
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Positron emission tomography (PET) with [F-18]2-fluoro-2-deoxy-D-giucose (FDG) may show negative results for bronchioloalveolar lung carcinoma. We investigated the correlation of Glut-1 glucose transporter expression with [F-18]FDG uptake in non-small cell lung cancer. Thirty-two patients with 34 non-small cell lung cancers (7 bronchioloalveolar carcinomas, 23 non-bronchioloalveolar adenocarcinomas, 3 squamous cell carcinomas, and I adenosquamous cell carcinoma) were studied. Final diagnoses were established by histology (via thoracotomy) in all patients. [F-18]FDG PET was performed 40 min after i.v. injection of 185 MBq [F-18]FDG. For semi-quantitative analysis of [F-18]FDG uptake, standardized uptake values (SUVs) were calculated. Glut-1 expression was studied in terms of the immunohistochemistry of paraffin sections using anti-Glut-1 antibody to determine the intensity (0-3) of Glut-1 immunoreactivity and percentage of the Glut-1-positive area. Of seven bronchioloalveolar carcinomas, six (85.7%) were negative for the expression of Glut-1, while only one (4.3%) of 23 non-bronchioloalveolar adenocarcinomas was negative (P < 0.0001). The percentages of Glut-1-positive area, as well as the SUVs, were significantly lower in bronchioloalveolar carcinomas (n = 7) (2.86% <plus/minus> 7.56% and 1.25 +/- 0.75, respectively) than in non-bronchioloalveolar adenocarcinomas (n = 23) (54.83% +/- 25.64%, P < 0.0001, and 3.94 <plus/minus> 1.93, P = 0.001, respectively). The degree of cell differentiation correlated with the percentage of Glut-1-positive area and SUVs in adenocarcinoma of the lung. Correlations between SUVs and the intensity of Glut-1 immunoreactivitv were also significant (intensities 0 and 1, n = 11, SUV 1.47 +/- 0.63; intensities 2 and 3, n = 23, SUV 4.78 +/- 2.13; P < 0.0001), The percentage of Glut-I-positive area correlated significantly with SUVs (n = 34, r = 0.658, P < 0.01). Overexpression of Glut-1 correlated with high [F-18]FDG uptake. These findings suggest that Glut-1 expression is related to [F-18]FDG uptake in non-small cell lung cancer. Glut-1 expression, as well as [F-18]FDG uptake, correlated with the degree of cell differentiation in adenocarcinomas, and both Glut-1 expression and [F-18]FDG uptake were significantly lower in bronchioloalveolar carcinomas than in non-bronchioloalveolar carcinomas.
引用
收藏
页码:1778 / 1785
页数:8
相关论文
共 43 条
[1]  
Aloj L, 1999, CANCER RES, V59, P4709
[2]  
AUERBACH O, 1991, CANCER, V68, P1973, DOI 10.1002/1097-0142(19911101)68:9<1973::AID-CNCR2820680921>3.0.CO
[3]  
2-Z
[4]  
BARSKY SH, 1994, CANCER-AM CANCER SOC, V73, P1163, DOI 10.1002/1097-0142(19940215)73:4<1163::AID-CNCR2820730407>3.0.CO
[5]  
2-J
[6]  
Brown RS, 1999, J NUCL MED, V40, P556
[7]  
Brown RS, 1996, J NUCL MED, V37, P1042
[8]  
Chung JK, 1999, J NUCL MED, V40, P339
[9]  
CLAVO AC, 1995, J NUCL MED, V36, P1625
[10]  
Gupta NC, 1996, J NUCL MED, V37, P943